Literature DB >> 35767128

Three-dimensional quantitative structural-activity relationship and molecular dynamics study of multivariate substituted 4-oxyquinazoline HDAC6 inhibitors.

Linan Zhao1, Le Fu2, Guangping Li1, Yongxin Yu1, Juan Wang1,3,4, Haoran Liang5,6,7, Mao Shu8,9,10, Zhihua Lin1,3,4, Yuanqiang Wang11,12,13.   

Abstract

3D-QSAR models were established by collecting 46 multivariate-substituted 4-oxyquinazoline HDAC6 inhibitors. The relationship of molecular structure and inhibitory activity was studied by comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA). The results showed the models established by CoMFA (q2 = 0.590, r2 = 0.965) and CoMSIA (q2 = 0.594, r2 = 0.931) had good prediction ability. At the same time, 3D-QSAR models met the internal verification, external verification and AD test. Ten new compounds were designed based on CoMFA and CoMSIA contour maps and their pharmacokinetic/toxic properties (ADME/T) were evaluated. It was found that most compounds have well safety profile and pharmacokinetic property. Then, we explored the interaction between HDAC6 and compounds by molecular docking. The results showed that the binding mode of the new compounds with HDAC6 was the same as the template compound 46, and the hydrogen bond and hydrophobic bond played a vital role in the binding process. Molecular dynamics simulation results showed that residues Ser531, His574 and Tyr745 played key roles in the binding process. All newly designed compounds had lower energy gap and binding energy than compound 46 according to DFT analysis and free energy analysis. This study provided a theoretical reference for designing compounds of higher activity and a new idea for the development of novel HDAC6 inhibitors.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  3D-QSAR; DFT; Histone deacetylase 6 inhibitors; Molecular docking; Molecular dynamics simulation

Year:  2022        PMID: 35767128     DOI: 10.1007/s11030-022-10474-w

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  35 in total

1.  DNA topoisomerase I-mediated nicking of circular duplex DNA.

Authors:  J J Champoux
Journal:  Methods Mol Biol       Date:  2001

2.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

Review 3.  Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

Authors:  S Salerno; F Da Settimo; S Taliani; F Simorini; C La Motta; G Fornaciari; A M Marini
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 4.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

5.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Authors:  Teru Hideshima; Jun Qi; Ronald M Paranal; Weiping Tang; Edward Greenberg; Nathan West; Meaghan E Colling; Guillermina Estiu; Ralph Mazitschek; Jennifer A Perry; Hiroto Ohguchi; Francesca Cottini; Naoya Mimura; Güllü Görgün; Yu-Tzu Tai; Paul G Richardson; Ruben D Carrasco; Olaf Wiest; Stuart L Schreiber; Kenneth C Anderson; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 6.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 7.  Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

Authors:  S Minucci; C Nervi; F Lo Coco; P G Pelicci
Journal:  Oncogene       Date:  2001-05-28       Impact factor: 9.867

8.  Non-peptide macrocyclic histone deacetylase inhibitors.

Authors:  Adegboyega K Oyelere; Po C Chen; William Guerrant; Sandra C Mwakwari; Rebecca Hood; Yunzhe Zhang; Yuhong Fan
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

9.  SAHA-based novel HDAC inhibitor design by core hopping method.

Authors:  Lan-Lan Zang; Xue-Jiao Wang; Xiao-Bo Li; Shu-Qing Wang; Wei-Ren Xu; Xian-Bin Xie; Xian-Chao Cheng; Huan Ma; Run-Ling Wang
Journal:  J Mol Graph Model       Date:  2014-09-06       Impact factor: 2.518

10.  HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer.

Authors:  Christian Mayr; Tobias Kiesslich; Sara Erber; Dino Bekric; Heidemarie Dobias; Marlena Beyreis; Markus Ritter; Tarkan Jäger; Bettina Neumayer; Paul Winkelmann; Eckhard Klieser; Daniel Neureiter
Journal:  Cancers (Basel)       Date:  2021-07-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.